Correction

de Heer, E C; Zois, C E; Bridges, E; van der Vegt, B; Sheldon, H; Veldman, W A; Zwager, M C; van der Sluis, T; Haider, S; Morita, T

Published in:
Journal of experimental & clinical cancer research

DOI:
10.1186/s13046-023-02800-3

Publication date:
2023

Journal of Experimental & Clinical Cancer Research

CORRECTION

Open Access

Correction: Glycogen synthase 1 targeting reveals a metabolic vulnerability in triple-negative breast cancer

E. C. de Heer[1†], C. E. Zois[2,3,4*†], E. Bridges[2†], B. van der Vegt[5], H. Sheldon[2], W. A. Veldman[1], M. C. Zwager[5], T. van der Sluis[5], S. Haider[6], T. Morita[7], O. Baba[7], C. P. Schröder[1,8], S. de Jong[1], A. L. Harris[2] and M. Jalving[1*]

Correction: ***J Exp Clin Cancer Res*****42, 143 (2023)**
https://doi.org/10.1186/s13046-023-02715-z

Following publication of the original article [1], an error was identified in Additional File 8: Fig. 6c. HCC1806 should have been U87MG. The correct Additional File 8: Fig. 6c caption should be:

(c) Well confluency of U87MG-shCtrl and -shGYS1 cells treated with different concentrations of GTPP, cultured in 5.6 mM glucose complete DMEM, was measured by Incucyte every 3 h.

The correction does not affect the overall Conclusion of the article. The original article has been corrected.

Published online: 28 August 2023

References

1. de Heer EC, Zois CE, Bridges E, et al. Glycogen synthase 1 targeting reveals a metabolic vulnerability in triple-negative breast cancer. J Exp Clin Cancer Res. 2023;42:143. https://doi.org/10.1186/s13046-023-02715-z.

Publisher's Note

†E.C. de Heer, C.E. Zois, E. Bridges contributed equally to this work.

The online version of the original article can be found at https://doi.org/10.1186/s13046-023-02715-z.

*Correspondence:
C. E. Zois
christos.zois@oncology.ox.ac.uk
M. Jalving
m.jalving@umcg.nl
[1]Department of Medical Oncology, University of Groningen, University Medical Center Groningen, PO Box 30.001, Groningen 9700 RB, The Netherlands
[2]Department of Oncology, Weatherall Institute of Molecular Medicine, Hypoxia and Angiogenesis Group, Cancer Research UK Molecular Oncology Laboratories, University of Oxford, Oxford OX3 9DS, UK
[3]Department of Radiotherapy and Oncology, School of Health, Democritus University of Thrace, Alexandroupolis, Greece
[4]Department of Oncology, MRC Weatherall Institute of Molecular Medicine, Molecular Oncology Laboratories, John Radcliffe Hospital, Oxford University, Oxford OX3 9DS, UK
[5]Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
[6]The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK
[7]Tokushima University Graduate School, 3-18-15, Kuramoto-Cho, Tokushima 770-8504, Japan
[8]Department of Medical Oncology, Antoni Van Leeuwenhoek-Netherlands Cancer Institute, Amsterdam, The Netherlands